The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Sometimes, a delay is caused by a patent review, so the PTO will compensate a pharmaceutical company by extending the life of ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

SNS Insider Projects a 7.66% CAGR as Major Depressive Disorder (MDD) Leads Demand, with North America Maintaining Market ...

Flagship Pioneering has signed yet another strategic-level deal with a big pharma group, with GSK the latest to tap into its network of biotech companies in an alliance that could be worth more ...

The drug, which was first approved in 2015, generated £1.6bn ($2.1bn) in revenue in 2023 for GSK, up 18% from the year before. It is predicted to see peak sales of $2.35bn in 2026, according to ...

M K Hamied has resigned from his position as Vice Chairman and Non-Executive Director of the pharma company, effective October 29, due to age and health reasons. The Board has appointed Adil ...

Global pharma giant GlaxoSmithKline Pharmaceuticals Ltd received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department on ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...